Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?: Commentary

Nature Clinical Practice Oncology

Volumn 2, Issue 8, 2005, Pages 388-389

  Coiffier, Bertrand ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

Bortezomib; Mantle cell lymphoma; Non Hodgkin's lymphoma

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CORTICOSTEROID; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER REGRESSION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FOLLICULAR LYMPHOMA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEUTROPHIL CHEMOTAXIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SHORT SURVEY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 30944450600     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0229     Document Type: Short Survey

References (5)

1. Feugier P et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma. A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117-4126
2. Coiffier B and Reyes F (2005) Best treatment of aggressive lymphomas: A French perspective. Oncology 19 (Suppl): 7-15
3. Coiffier B (2004) Dose intensity or monoclonal antibody in first-line treatment. Hematol J 5 (Suppl 3): S154-S158
4. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360
5. Goy A et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675